Zydus receives final approval from the USFDA for Clobazam Tablets

Deepthi | Myequity news | Date : 23-10-2018 14:55:00 IST

Zydus Cadila has received the final approval from the USFDA to market Clobazam Tablets, (US RLD — ONFI® Tablet), 10 mg and 20 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Clobazam is used in combination with other medications to treat seizures caused by a paediatric epilepsy syndrome (termed as Lennox-Gastaut syndrome) that also causes developmental and behavioural problems.

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research—based pharmaceutical company by 2020


More from Myequity